Table 4.
Summarized data of clinical response and toxicity to chemoimmunotherapy and cTRT
| Response to systemic therapy (n, %) | ||
|---|---|---|
| PD | 1 | 5.0% |
| SD | 2 | 10.0% |
| PR | 17 | 85.0% |
| CR | 0 | 0.0% |
| Not assessed | 0 | 0.0% |
| Local response to TRT (n, %) | ||
| PD | 2 | 10.0% |
| SD | 8 | 40.0% |
| PR | 7 | 35.0% |
| CR | 1 | 5.0% |
| Not assessed | 2 | 10.0% |
| Progression (n,%) | 17 | 85% |
| PFS in months (median, IQR) | 6.7 | 5.8-7.5 |
| Local progression (n, %) | 10 | 50.0% |
| Local PFS in months (median, IQR) | 11.4 | 8.4-14.2 |
| Distant progression (n, %) | 17 | 85.0% |
| Time to distant progression (median, IQR) | 6.7 | 5.8-7.5 |
| Intracranial progression | 5 | 20% |
| Neurologic death (n, %) | 0 | 0% |
| Median FU in months (median, IQR) | 12 | 9.4-16.2 |
| Median OS in months (median, 95% CI) | 16.0 | 12.4-19.7 |
| Toxicity (n, %) | ||
| Grade 2 + esophagitis | 1 | 5.00% |
| Grade 2 + radiation pneumonitis | 0 | 0.00% |
Abbreviations: CI = confidence interval; CR = complete response; cTRT = consolidative thoracic radiation therapy; FU = follow up time; IQR = interquartile range; OS = overall survival; PD = progressive disease; PFS = progression-free survival; PR = partial response; SD = stable disease; TRT = thoracic radiation therapy.